1/28
08:45 am
pdsb
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
Medium
Report
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
1/22
09:15 am
pdsb
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 [Yahoo! Finance]
Low
Report
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 [Yahoo! Finance]
1/22
08:45 am
pdsb
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
Low
Report
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
1/9
08:45 am
pdsb
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint
Medium
Report
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint
12/9
08:00 am
pdsb
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan
High
Report
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan
12/2
08:30 am
pdsb
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)
Medium
Report
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)
11/25
01:15 pm
pdsb
PDS Biotechnology (NASDAQ:PDSB) had its price target lowered by analysts at B. Riley from $5.00 to $3.00. They now have a "buy" rating on the stock.
Low
Report
PDS Biotechnology (NASDAQ:PDSB) had its price target lowered by analysts at B. Riley from $5.00 to $3.00. They now have a "buy" rating on the stock.